Stay updated on Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page
- Check3 days agoChange DetectedThe study's list of identifiers now includes a line for '2014 ( U.S. NIH Grant/Contract )', indicating NIH funding for the trial.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page footer now displays Revision: v3.6.5, replacing v3.6.4, indicating a deployed software update to the site rather than a change to the study details.SummaryDifference0.1%

- Check32 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4 on the page, indicating a newer build of the site's underlying templates or scripts. This typically reflects minor fixes or updates to the page infrastructure rather than changes to study content.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page's revision tag changed from v3.6.2 to v3.6.3, indicating a new version of the page. This update updates the documentation/version metadata without altering the study content or visible details.SummaryDifference0.1%

- Check60 days agoChange DetectedThe page now displays Revision: v3.6.2, replacing the previous v3.6.0. This indicates a newer page revision.SummaryDifference0.1%

- Check75 days agoChange DetectedThe page now indicates recruitment is closed and adds new help sections, while updating the Intervention/Treatment label and the revision tag to v3.6.0.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page.